Details for Patent: 11,529,339
Which drugs does patent 11,529,339 protect, and when does it expire?
Patent 11,529,339 protects ZENBEXUS and is included in one NDA.
This patent has fourteen patent family members in twelve countries.
Summary for Patent: 11,529,339
| Title: | Combination therapy for the treatment of cancer |
| Abstract: | Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab. Additionally, provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab and dexamethasone. |
| Inventor(s): | Michael D. Amatangelo, Chad BJORKLUND, Anjan THAKURTA, Xiankang Hong, Mariana Cota |
| Assignee: | Celgene Corp |
| Application Number: | US16/588,318 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 11,529,339
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ZENBEXUS | iberdomide hydrochloride | CAPSULE;ORAL | 221075-001 | Aug 13, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | IN COMBINATION WITH DARATUMUMAB AND HYALURONIDASE-FIHJ AND DEXAMETHASONE FOR TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING A PROTEASOME INHIBITOR AND AN IMMUNOMODULATORY AGENT | ⤷ Start Trial | ||||
| Bristol Myers Squibb | ZENBEXUS | iberdomide hydrochloride | CAPSULE;ORAL | 221075-002 | Aug 13, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | IN COMBINATION WITH DARATUMUMAB AND HYALURONIDASE-FIHJ AND DEXAMETHASONE FOR TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING A PROTEASOME INHIBITOR AND AN IMMUNOMODULATORY AGENT | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,529,339
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019351811 | ⤷ Start Trial | |||
| Brazil | 112021006318 | ⤷ Start Trial | |||
| Canada | 3114401 | ⤷ Start Trial | |||
| China | 112839658 | ⤷ Start Trial | |||
| Eurasian Patent Organization | 202190865 | ⤷ Start Trial | |||
| European Patent Office | 3860610 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
